perspective, First Welcome, and Thank XXXX from Quarter really well. you, LaViscount, Financial Medical's Officer we families appreciate doing I'm your joined to hope of and and Chief home on it. Conference is our everyone, crazy Diego. safe Chief Operating this I Call. everyone certainly, hope Joyce our is Officer. Earnings the Helius -- by I this time. is and your everyone communities call that And in evening
agenda discussing that U.S. recent detailed call. followed quarter then additional up a light you then during and me I for the I'll today's of our and progress in I'll in and I'll secure first thoughts quarter we've enhance caused it detail a revenue the and progress quarter conditions. the COVID-XX by financial closing with in our sheet provide and the capital questions. made Joyce for months. business provide process first before results by updates our quick of to open made results will the begin disruption and a balance you regulatory review pandemic. discuss our few the Joyce operational Let recent with we on by provide in Canada, our
using feedback support share to formal like view the our and to we to PoNS, that clinical from the patients clinicians consistent real-world continues we trials. authorized and patients in begin program, the of performance our into is and that the Before treating clinics continue the motivates performance and our I ones with Canada PoNS certainly our encourages This device employees. receive I'd the that their treatment loved observed in
it we gratifying to While treatment, that of in of upon majority patients difference make not the the everyone extremely be responds treat. to lives heartwarming a able is significant and
a regulatory let's in our first prioritize the the that start with the important of our of to during trials. to classification In multiple This the clinical decision MS, PoNS With and we as indication included data de in review that pursue to have Canada. we background, Health made an a or sclerosis, as progress was in our U.S. Canada. to U.S., And strategic quarter pathway the novo the of MS device. the on peer-reviewed decision bit first two submission quality our based more, little describe an
improvements Index, the showed gait, and group Gait versus Dynamic DGI, greater of demonstrated to in risk group that's active statistically or falls. clinical the an a individual's balance of measure One trials control assess
study The working PoNS and while can performance motor also enhance other that driving neuroplasticity. stimulation suggested memory
improvement from evidence -- in gathered U.S. novo sufficient significant results functional profile as in believe sorry, our in a which the baseline by our in In I'm data based required the risk-benefit validated addition, profile showed risk We database generated the we've de demonstrate the Canada, assessment. favorable on gait statistically to real-world are pathway
this X believe thus, significant the a to for the with be to Importantly, we is therapeutic also population this U.S. FDA. us million living business estimated MS patient in significant a unmet medical condition. represents MS be necessity the from is that another nearly And medical to standpoint, need driver individuals a high area. with pursue by deemed
value believe our believe U.S. importantly, We in our the we clearance obtain for this PoNS we pathway first regulatory this highest most backdrop, the and represents a device. path. shareholders to effective efficient for will as this create With pathway
to remained affected have pursuing been and on by Importantly, of COVID-XX this we aggressively the our in pursuit pandemic, significantly indication focused not our has initiative. MS date,
pace While anticipate very the for for future and impacts our been of half continue progress the second pandemic on classification of submitting XXXX. our unknown, de remains novo regulatory to MS with pleased submission in of we've
II medical In be in one; regular and MS, goal specifically on addressable label, treatment, focus receive marketing to U.S. we us third, with driven label novel Class license strategy Canada, to to of near-term bringing Canada XX, market this to first, performance XX. Health excited of the that amendment on build I XX,XXX scientific by the earlier objectives; high expansion submitted remarks. that continues our approximately very our the February in three support device our March strategy, expansion evidence in from our in application for with in opportunity to on We Canadian specifically market sound my our expand to to MS and second, increases market individuals to our PoNS primary regulatory our authorization generate patients for our MS. our therapy based which discussed Canada; Canada. innovative check drive unmet This Canadian our were label significantly living a enabling in credibility data to also Canada, needs, addressable On will
the of In in the world. highest incidents one fact, it's
clinicians pursue proud severity option. improve a have of nature their new to MS to of MS. their motivated Patients incredibly potential of are option chronic a potentially symptoms we walk, seen have ability and restore the and even with non-implantable this to making to We're can therapy novel relieve patients their on that neurodegenerative to of nondrug, that progressive has provide these we're and excited focusing this that debilitating the symptoms. patients lessen Given treatments aware are and treatment them to highly potential disease, the
our to Lastly, chronic of due injury, traumatic briefly U.S. I deficit the of indication brain the want or for pursuit to balance discuss mild-to-moderate treatment mmTBI.
of and hold COVID-XX for future. other our impacts related this research. TBI-related trial is as temporarily clinical all and across trial on on potential to U.S. the has continuing TBI-XXX trial a the in seek to funding are foreseeable Canada. Accordingly, order been We regulatory sources of The activity the result initiative execute halted
Now, let's turn first compared year during XXXX revenue the $XXX,XXX of of reported the total performance quarter. in to quarter our to prior the quarter. first in $XXX,XXX revenue We
of driven PoNS XXXX, to of locations both Our was in neuroplastic been periods to by neuroplastic the that was -- authorized sorry, In Canada review our were have largely sales in our authorized that in -- quarter the of XXXX. clinic clinics first to I'm provide neuroplasticity beginning revenue prior comprised sales of treatment.
Canada. PoNS XXXX during strong originally of XXXX, total locations began are the Both a for to we to clinic these to PoNS treatment locations quarter of device in we -- clinical In our patients first eagerly in this revenue sales initial our as reminder, the we in a commercializing benefited X authorized launched, began when of participated clinics clinical with treatment clinic trial, provide be and waiting trials database our who period. were As Canada. our two had from PoNS cleared significant
Looking detail. at in more performance revenue our
expectations. performance revenue was first XXXX Our our the during two of consistent months with
our I locations However, detail the in this prepared treatment. disruption to impacted our temporary was of led later in provide remarks. that significantly in clinic been have pandemic, by COVID-XXXX will to business weeks last more and the disruption discuss PoNS the authorized my of which caused its by closure the March, two impact
our of of we on commercial By overview an to positioned to XXXX began background, progress Canada. progress well our operational in way Canada. in build Moving
in treatment doing efficiently awareness as credibility authorized treatment. direction this During by increasing and we patient so authorizing the we drive new Canadian possible. goal The with building has approach, training process our of access, starts pace improved the with based targeting quarter, that on a business adoption established operations for over approach and identifying, significantly of PoNS. time for our the In our Canada for and connection treatment as for to engage PoNS provide improving new the to the an we streamlined our our strategy of clinics criteria clinics, PoNS the with
now we're a that clinics have neurorehabilitation credibility. commercial on large Specifically, existing to enhance targeting focus
systems to encouraging clinical studies with are model the facilitate with of to with designed relationships respect have of adoption the device conditions cost drive by treatment implemented -- significant patient the focusing public our finally, experience referral hospital to a neurological also encouraged experience are that also We've payer upfront with on to reducing reputable pricing We we with access. And awareness. like we're of treatment neurorehabilitation a clinicians our clinics the clinics networks new PoNS drive activities reimbursement by for established treatment, patients and through programs.
the made Armed pricing authorizing provide Canadian and capacity new to with strategy, progress first new the locations impressive alone. commercial this clinic PoNS our in our quarter, targeting first quarter treatment, doubling X team during
drive better as post-COVID impact big a quarter, new of efficiency adoption focus innovative has the us technology operational made the PoNS recovery driving to in of leaving soon as first starts patient our begins. our Our on business positioned
patient Like in the governments authorized treatments industry, slow XX to treatments, locations and the suspend emergency are PoNS many end patients. impacted to to has spread the the emergence the Canada. financial to select pandemic services our non-life-saving new were closed. provide operational required In of our for March, performance of of clinic been implement limit performance been COVID-XX implemented and the that by in provincial policies other clinics its March, PoNS restrictions than that adversely all to authorized to have medical companies and in At treatment temporarily Canada territorial provide began
of last performance As was during the result, March couple of a weeks our impacted. significantly
their the of patients the of virtual at-home shutdown, to the the shutdown of of who in-clinic Throughout with -- clinics initiation via their portion continue COVID-XX clinics support the support weeks two-week the and have completed via XX of prior means. the with the were to treatment. able All
subside. our was in been impacts offices the regions. to IT With safely pandemic protect and enabled that respect -- to to COVID-XX health to their to policies that them COVID-XX proactively employees mitigate impact this are respect our to the work productively also commercial work. we our we've their remotely. Helius that the employees our our reacted that of we closed with infrastructure and and pleased also well federal quickly have ensure our prepared to by With activities, to and -- we and the of instructed say when pandemic all employees I'm Most own COVID-related important continue notably, prepared help to we enacted physical created positioned respect enable changes were the local of an made business, that
the to activities First, monitoring engaged any this period. with supportive in authorized challenging closely PoNS clinics we're of in our them need provide
while Canada discussions, very business been in to many We've targeted they second, cultivate relationships team in clinics new this -- internal while our has new prospective receptive with continuing to our been are team engaging criteria specifically internal have team visit been target via engage means. person to to with find unable clinics our our I'm And pleased that sorry, and in with virtual in way. clinics to
Stepping back.
considerable the to first achieve PoNS toward in goal. that quarter, primary expenditure technology getting made During progress goal the we our scrutinize to efficiently our every U.S. and continue cleared of
building value approximately During through activities the development the patients manage and by to U.S. shareholders, operational our awareness quarter, goals -- submission the and activities. and operations. vigorously our Canadian for to our market raised clearance operations our access, for highest the on the our of support in continue our expenses our we MS technology gross $X that million and yield namely treating credibility We'll proceeds and focus to
and remains pandemic Canada financial unprecedented unable COVID-XX highly timing expectations recovery we're future currently recovers the magnitude uncertain, As ongoing times. performance world to the and are and for of from the pace, these U.S. provide the in until
we position MS in by treatment soon pursue subsides. as patient we're adoption U.S. our Canada initiatives pandemic the regulatory commercial we're Helius However, our activity to expanded in COVID-XX and clearance PoNS access continued on of to that drive as pace encouraged focused the and as of
financials. With over to me it the that, through first let to turn you walk Joyce quarter
